Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients (Q24194490)

6

0 references

Laurence Le Cleach

object named as

Laurence Le Cleach

1

0 references

Annabel Maruani

4

object named as

Annabel Maruani

0 references

author name string

Giao Do

3

0 references

Benedicte Lebrun-Vignes

5

0 references

Olivier Chosidow

Cochrane Database of Systematic Reviews

7

0 references

language of work or name

English

0 references

publication date

3 August 2014

0 references

published in

0 references

page(s)

CD009036

0 references

issue

8

0 references

cites work

Effects of long-term acyclovir chemosuppression on serum IgG antibody to herpes simplex virus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

O3-S5.02 Frequent breakthrough genital HSV-2 shedding on standard and high dose valacyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Natural history of genital herpes simplex virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Uncertainty in heterogeneity estimates in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Clinical practice. Genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Guidance on management of asymptomatic neonates born to women with active genital herpes lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

A pooled analysis of the effect of condoms in preventing HSV-2 acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Genital herpes and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Adjustment for reporting bias in network meta-analysis of antidepressant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Validation of the genital herpes treatment satisfaction questionnaire (GHerpTSQ) in status and change versions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Prophylactic oral acyclovir in recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A double-blind, placebo-controlled trial of the effect of chronically administered oral acyclovir on sperm production in men with frequently recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A prospective study of the effects of acyclovir treatment on the HSV-2 lymphoproliferative response of persons with frequently recurring HSV-2 genital infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Long-term oral acyclovir treatment prevents recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

European guideline for the management of genital herpes, 2010.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

Recurrence rates in genital herpes after symptomatic first-episode infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009036.PUB2

7 January 2021

10.1002/14651858.CD009036.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

843841

843841

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference